Skip to content Skip to footer
Subscribe Now
VIEWPOINTS_John Orwin_2023
VIEWPOINTS

John Orwin, President, and CEO at Atreca Shares his Views on Developing Novel Therapies for Cancer

Shots:John spoke about the development of a T cell engaging bispecific antibody directed against a novel solid tumor target under Atreca’s existing collaboration with XencorHe also talked about how this joint program combines the Atreca-discovered antibody, APN-346958, with Xencor’s XmAb CD3 bispecific antibody platformThe interview gives an understanding of Atreca’s focus on…
June 20, 2023

Read more

VIEWPOINTS_Anand Patel_2023
VIEWPOINTS

Anand Patel, CMO, of Conquest Research and a Principal Investigator Shares Insights from the Significant Benefits of LX9211

Shots:Anand briefed PharmaShots about the study design and the results from the RELIEF-DPN-1 trial of its investigational drug LX9211 presented at the 16th Annual Pain Therapeutics SummitHe spoke about how LX9211 met its primary endpoints and how the drug shows considerable promise as a novel therapeutic medication for the treatment of painful diabetic…
June 19, 2023

Read more

VIEWPOINTS_Philippe Halfon_2023
VIEWPOINTS

Philippe Halfon, President & Founder of Genoscience Pharma Shares Insights from the P-IIb Trial of Ezurpimtrostat to Treat Hepatocarcinoma

Shots:Philippe talked about the launch of the ABE-LIVER P-IIb study evaluating Ezurpimtrostat to treat hepatocarcinoma in combination with atezolizumab (an anti-PDL1) and bevacizumab (an antiangiogenic agent)He also gave a brief on the study design and talked about the efficacy of Ezurpimtrostat with atezolizumab & bevacizumab, compared to SOC aloneThe interview gives an…
June 15, 2023

Read more

VIEWPOINTS_Rui Avelar_2023
VIEWPOINTS

Rui Avelar, CMO and Head of R&D at Evolus Shares Insights from Interim P-II Data Results Evaluating an “Extra-Strength” Formulation of Jeuveau

Shots:Rui gave the details about the “extra-strength” formulation of Jeuveau. He highlighted the study design and results of the trial evaluating  Jeuveau. The data indicated that the “extra-strength” formulation of Jeuveau at 40U achieved a duration profile of 6 months or 26 weeksThe data was presented at the 2023 IMCAS World Congress in…
June 13, 2023

Read more

VIEWPOINTS_Anas Batikhi_2023
VIEWPOINTS

Anas Batikhi, Founder & CEO at Santechture Shares on RCM-Tech, A Necessity in The Healthcare Industry

Shots:Anas spoke about revenue cycle management in the healthcare sector and the traditional challenges in the healthcare RCMHe also elaborated on how the evolving technologies can help to overcome the challenges in healthcare revenue cycle managementThe interview shows how Santechture is developing smart AI-based and cloud-based solutions to help healthcare providers develop…
June 2, 2023

Read more

VIEWPOINTS_Gregory Bell_2023
VIEWPOINTS

Gregory Bell, CMO at Attralus Shares Insights from its License Agreement with Ossianix to Use Ossianix’s Brain Shuttle Technology

Shots:Gregory initially spoke about the Attralus licensing agreement with Ossianix’s brain shuttle technology to enhance the targeted delivery of novel pan-amyloid removal candidates for use in neurodegenerative disorders such as Alzheimer’s DiseaseHe also talked about how Ossianix VNAR antibody-based brain shuttle TXP1 will help Attralus to deliver AT-04, its developmental PAR therapeutic candidate,…
May 30, 2023

Read more

VIEWPOINTS_David Pendlebury_2023
VIEWPOINTS

David Pendlebury, Head of Research Analysis, Institute for Scientific Information Shares Insights from its Annual Highly Cited Researchers List

Shots:David first talked about Clarivate’s Highly Cited Researchers 2022 list. He said that the list picks out 6,938 individuals at universities, research institutes, and commercial organizations across 69 countries/regionsHe also elucidated the methodology used by Clarivate to create the list and how the pharma companies can benefit from this list to strengthen their…
May 29, 2023

Read more

VIEWPOINTS_Dr. Samiah Al-Zaidy_2023
VIEWPOINTS

Dr. Samiah Al-Zaidy, VP of Clinical Development at Passage Bio Shares Insights on Additional Interim Data from the Imagine-1 Study for GM1 Gangliosidosis

Shots:Samiah Al-Zaidy spoke about the interim clinical data from Imagine-1, P-I/II trial of PBGM01 for GM1 gangliosidosis presented at the 19th Annual WORLDSymposium 2023She also talked about how the presentation at WORLDSymposium contributed to raising awareness about GM1 Gangliosidosis which is a rare and fatal diseaseThe interview showcases Passage Bio’s mission to…
May 22, 2023

Read more

VIEWPOINTS_Dr. Harmony Garges_2023
VIEWPOINTS

Dr. Harmony Garges, CMO at ViiV Healthcare, Shares Insights on Positive Findings from the SOLAR Study of Cabenuva

Shots:Dr. Harmony gave the details about the positive 12-month findings from the P-IIIb SOLAR trial of the first and only complete long-acting injectable regimen Cabenuva vs. BiktarvyShe also talked about the comparison of the Cabenuva regimen with the other existing & developing products for HIV including the Biktarvy regimenThe interview gives an…
May 18, 2023

Read more

Load more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]